Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) shares hit a new 52-week low on Wednesday . The company traded as low as C$0.20 and last traded at C$0.21, with a volume of 85632 shares traded. The stock had previously closed at C$0.26.
Aptose Biosciences Stock Performance
The firm has a market capitalization of C$9.04 million, a PE ratio of -0.04 and a beta of 1.36. The stock’s 50 day moving average price is C$0.30 and its two-hundred day moving average price is C$0.44. The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More
- Five stocks we like better than Aptose Biosciences
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
